Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Paul A. Romness
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Beta
- -0.64
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -25.29
Financials
Net Income
$-8.63MEBITDA
$-8.45M-1055.4%Free Cash Flow
$-5.53MEPS (diluted)
$-0.20Shares Outstanding (diluted)
43.90M+227.3%Operating Expenses
$8.58BCash & Debt
$205.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-28.75M | $-0.98 |
| 2024 | $0.00 | $-8.88M | $-0.52 |
| 2023 | $0.00 | $-7.79M | $-0.39 |
| 2022 | $0.00 | $-6.25M | $-0.28 |
| 2021 | $0.00 | $-7.42M | $-0.33 |
| 2020 | $0.00 | $-6.0K | $-0.00 |
Valuation
OSTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+33.33%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Neutral
…ubenstein Public Relations (RPR), a leading full-service communications firm, announces it has been named the Agency of Record for OS Therapies, Inc. (NYSE American: OSTX), the world leader in gene-edited, Listeria-based cancer immunotherapies. Recently, OS Therapies announced that it has reached a critical point in achieving entry into the global market with access into the U.K national patient registry and UK Clinical Practice Research Datalink (CPRD) by the U.K. Medicines and Healthcare produ…
View source ↗ - Newsbenzinga.com·2d ago·Neutral
OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment OS Therapies Inc. (NYSE:OSTX) announced a statistically significant three-year overall survival benefit for patients treated with OST-HER2 in its Phase 2b trial.
View source ↗ - Newsnewsfilecorp.com·52d ago·Negative
… U.K. waives Pediatric Investigation Plan (PIP) requirement New York and Rockville, Maryland--(Newsfile Corp. - August 17, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today reported financial results for the second fiscal quarter ended June 30, 2026, and provided business and regulatory updates. The Company is seeking to obtain a Biologics License Application (BLA) under the Accelerate…
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.13 per share
Typical surprise -58.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.20 vs $-0.18miss
- Mon, May 18$-0.27 vs $-0.17miss
- Tue, Mar 31$-0.35 vs $-0.14miss
- Fri, Nov 14$-0.21 vs $-0.16miss
- Tue, Aug 19$-0.19 vs $-0.15miss
- Thu, May 15$-0.18 vs $-0.11miss
Estimates and results for OSTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OSTX officers and directors.
- Bought
- —
- Sold
- $642k
0 trades
5 trades
- Auerbach Shalomsold
- Auerbach Shalomsold
- Auerbach Shalomsold
- Auerbach Shalomsold
- Auerbach Shalomsold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OSTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.